Inpatient and Outpatient Orderable

Systemic Sclerosis (Scleroderma) 12 Antibodies Panel 2 Build info

Synonyms

  • SYSTEMIC SCLEROSIS (SCLERODERMA) 12 ANTIBODIES PANEL 2
  • SYSSCLER
  • LAB10910

Procedure Name

SYSTEMIC SCLEROSIS (SCLERODERMA) 12 ANTIBODIES PANEL 2

Procedure Master Number

LAB10910

Procedure ID

114318

Clinical Info

Systemic sclerosis (SSc) is an autoimmune disease characterized by vascular abnormalities, and cutaneous and visceral fibrosis.

Specimen Sources

 Blood, Arterial Blood, Capillary Blood, Central Line Blood, Venous

Specimen Types

 Blood

Container

Gold Top Tube

Collection Instructions

Container/Tube: Gold Top Tube
Specimen: 0.5 mL serum ( 0.3 mL min)
Transport Temperature: Room Temperature

Specimen Volume

Transport Instructions

Specimen Stability

7 Days Room Temperature
14 Days Refrigerated
21 Days Frozen

Methodology

Line Blot
This test was developed and its analytical performance characteristics have been determined by
Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated
pursuant to the CLIA regulations and is used for clinical purposes.

Days Performed

TAT: 4-6 Days

Performing Laboratory

Quest Diagnostics Nichols Institute- San Juan Capistrano, CA

CPT

86235 x 10
84182 x 2

PDM

 225705

Only Orderable at Locations:

 Orderable Everywhere

Results
Component Name Base Name Common Name External Name
SCL-70 SCL70 SCL 70 Scl-70
CENP-A CENPA CENP A CENP-A
CENP-B CENPB CENP B CENP-B
RP11 RP11 RP11 RP11
RP155 RP155 RP155 RP155
U1-SNRNP RNP A U1SNRNPA U1 SNRNP RNP A U1-snRNP RNP A
U1-SNRNP RNP C U1SNRNPC U1 SNRNP RNP C U1-snRNP RNP C
U1-SNRNP RNP-70KD UQSNRNP70KD U1 SNRNP RNP 70KD U1-snRNP RNP-70kd
FIBRILLARIN FIBRILLARIN FIBRILLARIN Fibrillarin
TH/TO THTO TH TO Th/To
PM/SCL-100 PMSCL100 PM SCL 100 PM/Scl-100
PM/SCL-75 PMSCL75 PM SCL 75 PM/Scl-75

Result Interpretation

See Report

  Systemic sclerosis (SSc) is an autoimmune disease characterized by vascular abnormalities, and cutaneous and visceral fibrosis. Some antibodies are considered highly specific for SSc,
including Scl-70 (anti-topoisomerase 1) antibody, anti-centromere (CENP) antibodies,
and anti-RNA polymerase III antibody and are classification criteria for disease
defined by the American College of Rheumatology. Centromere antibodies are
found in patients with a limited form of cutaneous systemic sclerosis, "CREST"
syndrome, a complex of subcutaneous calcinosis, Raynaud's phenomenon,
esophageal dysmotility, sclerodactyly, and telangiectasias. RNA polymerase III
antibodies target RNAP III epitopes 11 and 155.
Antibodies to three major components of U1-snRNP (snRNP RNP A,
U1-snRNP RNP C, U1-snRNP RNP-70kd): U1- are associated with scleroderma
and inflammatory myopathy overlap syndromes. Anti-fibrillarin (anti-U3RNP)
antibodies are associated with diffuse cutaneous SSc, frequent visceral involvement,
and especially renal and cardiac involvement. In African-American patients, anti-fibrillarin
antibodies are associated with severe pulmonary disease, pulmonary hypertension,
severe small bowel involvement, and a poor prognosis. Anti-Th/To antibodies primarily
bind to two proteins of the mitochondrial RNA processing (MRP) and the ribonuclease P complexes,
are present in 1-13% of SSc patients, and are rarely found in other diseases.
Anti-Th/To antibodies are primarily associated with localized cutaneous scleroderma,
and associated with pericarditis, interstitial lung disease and a high frequency
of “intrinsic pulmonary hypertension, and a poorer prognosis. Autoantibodies
to PM/Scl, the human exosome complex, are found in polymyositis/scleroderma
overlap syndromes. The majority of anti-PM/Scl reactivity is directed to one of
two proteins: PM/Scl100 and/or PM-Scl75.

Forms
edit